Prolonged survival and phenotypic correction of Akp2-/- hypophosphatasia mice by lentiviral gene therapy

Journal of Bone and Mineral Research

Volumn 26, Issue 1, 2011, Pages 135-142

  Yamamoto, Seiko ^a,b   Orimo, Hideo ^a   Matsumoto, Tae ^a   Iijima, Osamu ^a   Narisawa, Sonoko ^c   Maeda, Takahide ^b   Millán, José Luis ^c   Shimada, Takashi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Alkaline phosphatase; Calcification; Enzyme replacement; Epilepsy; Lentiviral vector

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE ISOENZYME; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE THERAPY; HYPOPHOSPHATASIA; JUGULAR VEIN; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PHYSICAL ACTIVITY; RADIODIAGNOSIS; SEIZURE; SKELETON; SURVIVAL; VIRAL GENE THERAPY;

ALKALINE PHOSPHATASE; ANIMALS; FOOT; GENE THERAPY; HYPOPHOSPHATASIA; LENTIVIRUS; MICE; PHENOTYPE; SURVIVAL ANALYSIS; TIBIA;

EID: 78650956613     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.201     Document Type: Article

References (41)

1. Rathbun JC., Hypophosphatasia: a new developmental anomaly. Am J Dis Child. 1948; 75: 822-831.
2. Whyte MP., Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev. 1994; 15: 439-461.
3. Whyte MP., Hypophosphataia. In:, Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, eds. The Metabolic and Molecular Bases of Inherited Deseases 8th ed, Vol IV. New York: McGraw-Hill, 5319-5329. 2002.
4. Pimstone B, Eisenberg E, Silverman S., Hypophosphatasia: genetic and dental studies. Ann Intern Med. 1966; 65: 722-7229.
5. Seetharam B, Tiruppathi C, Alpers DH., Hydrophobic interactions of brush border alkaline phosphatases: the role of phosphatidyl inositol. Arch Biochem Biophys. 1987; 253: 189-198.
6. Millán JL., Mammalian Alkaline Phosphatases. From Biology to Applications in Medicine and Biotechnology. Weinheim, Germany: Wiley-VCH, 2006.
7. Russell RG., Excretion of Inorganic Pyrophosphate in Hypophosphatasia. Lancet. 1965; 2: 461-464.
8. Russell RG, Bisaz S, Donath A, Morgan DB, Fleisch H., Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest. 1971; 50: 961-969.
9. Whyte MP, Mahuren JD, Vrabel LA, Coburn SP., Markedly increased circulating pyridoxal-5'-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest. 1985; 76: 752-756.
10. Whyte MP, Mahuren JD, Fedde KN, Cole FS, McCabe ER, Coburn SP., Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5'-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. J Clin Invest. 1988; 81: 1234-1239.
11. McCance RA, Camb MD, et al. The excretion of phosphoethanolamine and hypophosphatasia. Lancet. 1955; 268: 131.
12. Fleisch H, Maerki J, Russell RG., Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc Soc Exp Biol Med. 1966; 122: 317-320.
13. Whyte MP, Valdes R Jr, Ryan LM, McAlister WH., Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr. 1982; 101: 379-386.
14. Whyte MP, McAlister WH, Patton LS, et al. Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients. J Pediatr. 1984; 105: 926-933.
15. Macpherson RI, Kroeker M, Houston CS., Hypophosphatasia. J Can Assoc Radiol. 1972; 23: 16-26.
16. Weninger M, Stinson RA, Plenk H Jr, Bock P, Pollak A., Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. Acta Paediatr Scand Suppl. 1989; 360: 154-160.
17. Whyte MP, Landt M, Ryan LM, et al. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest. 1995; 95: 1440-1445.
18. Whyte MP, Kurtzberg J, McAlister WH, et al. Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res. 2003; 18: 624-636.
19. Cahill RA, Wenkert D, Perlman SA, et al. Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. J Clin Endocrinol Metab. 2007; 92: 2923-2930.
20. Tadokoro M, Kanai R, Taketani T, Uchio Y, Yamaguchi S, Ohgushi H., New bone formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia. J Pediatr. 2009; 154: 924-930.
21. Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, MacGregor GR., Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat Genet. 1995; 11: 45-51.
22. Narisawa S, Frohlander N, Millán JL., Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn. 1997; 208: 432-446.
23. Fedde KN, Blair L, Silverstein J, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res. 1999; 14: 2015-2026.
24. Hessle L, Johnson KA, Anderson HC, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002; 99: 9445-9449.
25. Millán JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008; 23: 777-787.
26. Nishioka T, Tomatsu S, Gutierrez MA, et al. Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab. 2006; 88: 244-255.
27. Ishizaki J, Waki Y, Takahashi-Nishioka T, Yokogawa K, Miyamoto K., Selective drug delivery to bone using acidic oligopeptides. J Bone Miner Metab. 2009; 27: 1-8.
28. Greenberg CR, Mhanni A, Catte D, et al. Interim results of adults and infants with hypophosphatasia treated with bone-targeted human recombinant alkaline phosphatase ENB-0040. Mol Genet Metab. 2009; 98: 7.
29. Sogabe N, Oda K, Nakamura H, et al. Molecular effects of the tissue-nonspecific alkaline phosphatase gene polymorphism (787T > C) associated with bone mineral density. Biomed Res. 2008; 29: 213-219.
30. Hanawa H, Yamamoto M, Zhao H, Shimada T, Persons DA., Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol Ther. 2009; 17: 667-674.
31. Segura MM, Kamen A, Garnier A., Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv. 2006; 24: 321-337.
32. Kutner RH, Puthli S, Marino MP, Reiser J., Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol. 2009; 9: 10.
33. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K., Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 2002; 9: 1155-1162.
34. Hanawa H, Hargrove PW, Kepes S, Srivastava DK, Nienhuis AW, Persons DA., Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia. Blood. 2004; 104: 2281-2290.
35. Narisawa S, Wennberg C, Millán JL., Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol. 2001; 193: 125-133.
36. Goseki M, Oida S, Sasaki S., Detection of minor immunological differences among human "universal-type" alkaline phosphatases. J Cell Biochem. 1988; 38: 155-163.
37. Hoshi K, Amizuka N, Oda K, Ikehara Y, Ozawa H., Immunolocalization of tissue non-specific alkaline phosphatase in mice. Histochem Cell Biol. 1997; 107: 183-191.
38. Sugiyama O, Orimo H, Suzuki S, Yamashita K, Ito H, Shimada T., Bone formation following transplantation of genetically modified primary bone marrow stromal cells. J Orthop Res. 2003; 21: 630-637.
39. Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G., Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 2005; 19: 1093-1104.
40. Nienhuis AW, Dunbar CE, Sorrentino BP., Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006; 13: 1031-1049.
41. Baumgartner-Sigl S, Haberlandt E, Mumm S, et al. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone. 2007; 40: 1655-1661.